Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches

Lee, Hee-Jung; Choi, Heung‐Jin; Nowakowska, Aleksandra; Kang, Lin‐Woo; Kim, Minjee; Kim, Young Bong

doi:10.1007/s12275-023-00062-4

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization (WHO) announced the identification of the variant on December 18, 2020, and classified it as a "variant of concern" on December 24, 2020. Since its emergence, a lot of efforts have been made to develop effective vaccines and therapeutics (reviewed in [2][3][4][5][6][7][8][9][10][11][12] and references therein). Nevertheless, SARS-CoV-2 continues to pose a threat to public health, and the efficacy of antiviral measures need to be improved, particularly against variants, by elucidating the fundamental mechanisms of viral evolution and pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant

Kim,

Bae,

Goo

et al. 2023

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

Since its first report in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a grave threat to public health. Virus-specific countermeasures, such as vaccines and therapeutics, have been developed and have contributed to the control of the viral pandemic, which has become endemic. Nonetheless, new variants continue to emerge and could cause a new pandemic. Consequently, it is important to comprehensively understand viral evolution and the roles of mutations in viral infectivity and transmission. SARS-CoV-2 beta variant encode mutations (D614G, N501Y, E484K, and K417N) in the spike which are frequently found in other variants as well. While their individual role in viral infectivity has been elucidated against various therapeutic antibodies, it still remains unclear whether those mutations may act additively or synergistically when combined. Here, we report that N501Y mutation shows differential effect on two therapeutic antibodies tested. Interestingly, the relative importance of E484K and K417N mutations in antibody evasion varies depending on the antibody type. Collectively, these findings suggest that continuous efforts to develop effective antibody therapeutics and combinatorial treatment with multiple antibodies are more rational and effective forms of treatment.

show abstract